title: COSENTYX (Secukinumab).
authors: Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada.|Mediprobe Research Inc, London, Ontario, Canada; agupta@execulink.com.
authors: Aditya K
authors: AK
authors: Gupta
authors: Mediprobe Research Inc, London, Ontario, Canada.
authors: Kelly A
authors: KA
authors: Foley
authors: Department of Medicine, Baylor University Medical Center, Dallas, TX.|Departments of Dermatology and Family Practice, University of Texas Southwestern Medical School, Dallas, TX.|Dermatology Treatment and Research Center, Dallas, TX.
authors: William
authors: W
authors: Abramovits
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors*; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D020381:Interleukin-17; C555450:secukinumab